Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -26.40% | -43.36% | -71.84% | -15.38% | 10.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.40% | -43.36% | -71.84% | -15.38% | 10.98% |
| Cost of Revenue | -44.60% | -25.43% | -27.04% | -9.34% | 4.46% |
| Gross Profit | 46.82% | 23.69% | -224.69% | 8.96% | -3.72% |
| SG&A Expenses | -19.66% | -48.86% | -33.66% | -33.96% | -4.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.40% | -34.22% | -25.03% | -19.03% | -1.77% |
| Operating Income | 28.48% | 33.68% | 18.00% | 19.17% | 2.21% |
| Income Before Tax | 37.92% | 32.36% | 11.34% | 21.63% | -18.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.92% | 32.36% | 11.34% | 21.63% | -18.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.92% | 32.36% | 11.34% | 21.63% | -18.20% |
| EBIT | 28.48% | 33.68% | 18.00% | 19.17% | 2.21% |
| EBITDA | 27.58% | 34.04% | 16.53% | 17.95% | 2.30% |
| EPS Basic | 38.67% | 33.05% | 12.14% | 33.07% | 1.05% |
| Normalized Basic EPS | 17.43% | 33.04% | 12.13% | 33.06% | 36.38% |
| EPS Diluted | 38.67% | 33.05% | 12.14% | 33.07% | 1.05% |
| Normalized Diluted EPS | 17.43% | 33.04% | 12.13% | 33.06% | 36.38% |
| Average Basic Shares Outstanding | 1.23% | 1.04% | 0.90% | 17.08% | 19.45% |
| Average Diluted Shares Outstanding | 1.23% | 1.04% | 0.90% | 17.08% | 19.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |